Recent Advance in Near‐Infrared (NIR) Imaging Probes for Cancer Theranostics

Liu, Yuxin; Jia, Qi; Zhou, Jing

doi:10.1002/adtp.201800055

Cited by 37 publications

(26 citation statements)

References 145 publications

(296 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the remaining participant (8-mg cohort), green urine coloration first appeared in the 2-to 2.5-hour interval. Green urine was observed until 3 to 3.5 hours after dosing in 3 of the 4 participants in the indocyanine green, which are approved for use in other indications, [23][24][25] have revealed deficiencies in optical properties and route of administration and clearance, respectively, that make them unsuitable for such procedures. 12 To address this unmet need, novel NIRF agents are being developed.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

Murase

Takizawa

Galitz

et al. 2021

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Intraoperative ureter identification helps reduce the risk of ureteral injury. Currently, no suitable agents for real-time ureter visualization are approved. ASP5354 (TK-1) is a novel indocyanine green derivative. In this first-in-human phase 1, double-blind, sequential ascending-dose study, urethral catheters were placed in 6 healthy volunteers who were randomized to single-dose, intravenous ASP5354 0.1 mg (n = 4) or placebo (n = 2). Sequential dose escalations to 0.5-, 2-, 8-, and 24-mg ASP5354 in new cohorts were contingent upon Dose-Escalation Committee approval after review of pharmacokinetic (PK) and safety data. Blood and urine samples were collected over 24 hours following dose administration. Objectives were to assess the safety/tolerability and PK of ASP5354. Treatment-emergent adverse events (TEAEs) were reported in 3 (15%) and 2 (20%) participants in the ASP5354 and placebo groups, respectively. In the former, there were 6 TEAEs (5/6 grade 1-2). One ASP5354 participant experienced grade 3 pyelonephritis, attributed to the catheter. No TEAEs were related to ASP5354. Mean plasma terminal elimination half-life ranged from 2.1 to 3.6 hours, with near complete urinary excretion of unchanged ASP5354 within 24 hours after administration. Linear and dose-proportional PK were observed. These results support further evaluation of ASP5354 at doses up to 24 mg for intraoperative near-infrared fluorescence ureter visualization.

show abstract

Section: Pharmacokineticsmentioning

confidence: 99%

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

Murase

Takizawa

Galitz

et al. 2021

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

“…In the past 50 years, clinical practice has been going through a transition fueled by technological developments. Biomed ical engineering, [1][2][3][4][5][6][7][8][9] material science, [10][11][12][13][14][15][16][17][18] and artificial intel ligence (AI) [19][20][21][22][23][24] have been transforming the entire medical landscape: diagnostics, [25][26][27][28][29][30][31][32][33] drug development, 24,[34][35][36] drug delivery, [37][38][39][40][41][42][43][44][45][46] and data analytics. [47][48][49]…”

Section: Introductionmentioning

confidence: 99%

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

2020

View full text Add to dashboard Cite

The clinical team attending to a patient upon a diagnosis is faced with two main questions: what treatment, and at what dose? Clinical trials’ results provide the basis for guidance and support for official protocols that clinicians use to base their decisions upon. However, individuals rarely demonstrate the reported response from relevant clinical trials, often the average from a group representing a population or subpopulation. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally, the individual’s response to the treatment varies over time with the changes in his or her condition, whether via the indication or physiology. In practice, the drug and the dose selection depend greatly on the medical protocol of the healthcare provider and the medical team’s experience. As such, the results are inherently varied and often suboptimal. Big data approaches have emerged as an excellent decision-making support tool, but their application is limited by multiple challenges, the main one being the availability of sufficiently big datasets with good quality, representative information. An alternative approach—phenotypic personalized medicine (PPM)—finds an appropriate drug combination (quadratic phenotypic optimization platform [QPOP]) and an appropriate dosing strategy over time (CURATE.AI) based on small data collected exclusively from the treated individual. PPM-based approaches have demonstrated superior results over the current standard of care. The side effects are limited while the desired output is maximized, which directly translates into improving the length and quality of individuals’ lives.

show abstract

“…[10][11][12] To date, most research has been focused on the rational design and fabrication of an all-in-one nanotheranostic as an extremely valuable strategy with multifunctional theranostic performance. [13,14] Wang and co-workers designed a novel small-molecule dye DPP-BT, which showed a single NIR laser triggered multifunctional properties for NIR-II fluorescence/photoacoustic (PA)…”

mentioning

confidence: 99%

Biodegradable Silica‐Based Nanotheranostics for Precise MRI/NIR‐II Fluorescence Imaging and Self‐Reinforcing Antitumor Therapy

Zheng

Jia

et al. 2021

Small

View full text Add to dashboard Cite

cancer diagnosis including higher spatial and temporal resolution than the conventional NIR-I window fluorescence imaging (650-900 nm), mainly benefiting from the simultaneously suppressed tissue auto-fluorescence, photon scattering, and background interference. [3-5] In spite of significant improvements in NIR-II FL for imaging performance, accurate and wealthy information at different tissue penetration depths and scales cannot be effectively provided by a single imaging technology. [6,7] Magnetic resonance imaging (MRI) has outstanding performance in modern clinical medicine, offering higher spatial resolution than that of NIR-II FL. [8,9] Considering the desirable features of each imaging modality, integration of NIR-II FL and MRI may accurately delineate tumor by compensating their inherent limitations. Therefore, there is an urgent demand for an efficient imaging tool to achieve precise MRI/NIR-II FL dual-modal imaging of tumors. With the rapid development of biomedical engineering and nanotechnology, a variety of multimodal nanoprobes have been developed and provide accurate location and therapeutic improvement of tumor. [10-12] To date, most research has been focused on the rational design and fabrication of an all-in-one nanotheranostic as an extremely valuable strategy with multifunctional theranostic performance. [13,14] Wang and co-workers designed a novel small-molecule dye DPP-BT, which showed a single NIR laser triggered multifunctional properties for NIR-II fluorescence/photoacoustic (PA) Multi-modality cancer diagnosis techniques based on the second near-infrared window fluorescence (NIR-II FL, 1000-1700 nm) imaging have become the focus of research attention. For such multimodality probes, how to take advantage of the tumor microenvironments (TME) characteristics to better image diseases and combine efficient therapeutics to achieve theranostics is still a big challenge. Herein, a novel TME-activated nanosystem (FMSN-MnO 2-BCQ) employing degradable silica-based nanoplatform is designed, adjusting the ratio of intratumoral hydrogen peroxide (H 2 O 2)/glutathione (GSH) for magnetic resonance imaging (MRI)/NIR-II FL imaging and selfreinforcing chemodynamic therapy (CDT). Innovative bovine serum albumin (BSA)-modified fusiform-like mesoporous silica nanoparticles (FMSN) is fabricated as a carrier for NIR-II small molecule (CQ4T) and MRI reporter MnO 2. Remarkably, the BSA modification helped to achieve the dual-functions of high biocompatibility and enhance NIR-II fluorescence. The FMSN-MnO 2-BCQ with FMSN framework featuring a stepwise degradability in tumor interior released MnO 2 and BCQ nanoparticles. Through the specific degradation of MnO 2 by the TME, the produced Mn 2+ ions are effectively exerted Fenton-like activity to generate hydroxyl radical (•OH) from endogenous H 2 O 2 to eradicate tumor cells. More importantly, the GSH depletion due to the synergistic effect of tetrasulfide bond and MnO 2 in turn induced the oxidative cytotoxicity for self-reinforcing CDT.

show abstract

Recent Advance in Near‐Infrared (NIR) Imaging Probes for Cancer Theranostics

Cited by 37 publications

References 145 publications

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence

Biodegradable Silica‐Based Nanotheranostics for Precise MRI/NIR‐II Fluorescence Imaging and Self‐Reinforcing Antitumor Therapy

Contact Info

Product

Resources

About